According to a new report, published by KBV research, The Global Theranostics Market size is expected to reach $5.4 billion by 2030, rising at a market growth of 15.2% CAGR during the forecast period.
Digitalization and AI drive transformative changes in theranostics by enabling data-driven decision-making, predictive analytics, and automated image analysis. AI algorithms analyze large datasets of medical images, biomarker profiles, and clinical outcomes to identify patterns, predict disease progression, and optimize treatment algorithms. Machine learning techniques, deep learning models, and natural language processing (NLP) algorithms enhance diagnostic interpretations’ accuracy, efficiency, and reproducibility, supporting personalized medicine initiatives and precision healthcare delivery.
The Theranostics Centers segment would exhibit a CAGR of 15.6% during (2023 - 2030). Theranostic centers are dedicated facilities that provide integrated diagnostic and therapeutic services using advanced technologies and specialized expertise. These centers employ multidisciplinary teams of healthcare professionals, including radiologists, pathologists, oncologists, molecular biologists, and nuclear medicine specialists, with extensive experience and training in theranostic approaches.
The Radiopharmaceuticals segment is registering maximum revenue in the Global Theranostics Market by Product in 2022; thereby, achieving a market value of $2.4 billion by 2030. Advances in nuclear medicine technology, including cyclotron production, radiochemistry synthesis, and radiotracer development, have expanded the repertoire of radiopharmaceuticals available for theranostic applications. Novel radiolabeling techniques, isotopes, and ligands enable the synthesis of radiopharmaceuticals with enhanced stability, specificity, and pharmacokinetics for diagnostic imaging and therapeutic interventions.
The Bone Metastasis segment is experiencing a CAGR of 15.4% during (2023 - 2030). Bone metastasis is a common complication of advanced cancers, particularly prostate, breast, lung, and thyroid cancers. It occurs when cancer cells spread from the primary tumor to the bones, leading to skeletal complications such as bone pain, fractures, spinal cord compression, and hypercalcemia. The high prevalence of bone metastasis in cancer patients necessitates effective diagnostic and therapeutic strategies to assess disease extent, monitor treatment response, and alleviate symptoms, driving the demand for theranostics in this clinical setting.
Full Report: https://www.kbvresearch.com/theranostics-market/
The North America region dominated the Global Theranostics Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.3 billion by 2030. The Europe region is anticipated to grow at a CAGR of 14.8% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 16.2% during (2023 - 2030).
By End User
By Product
By Application
By Geography
Unique Offerings 
